FDA approves generic lenacapavir, expanding HIV prevention access to 120 countries

The FDA authorized a generic version of lenacapavir, a long-acting injectable HIV prevention drug, enabling faster access in 120 low- and middle-income countries. This marks a significant step in global HIV prevention, though manufacturing scale-up and distribution logistics remain uncertain. The move could substantially reduce new infections if widely adopted.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works